Vaxart Announces Updated Details for Annual Meeting
Vaxart, Inc. (NASDAQ: VXRT), a pioneering biotechnology firm, has recently announced the adjournment of its annual meeting of stockholders. This meeting will now reconvene on June 13, 2025, at 8:30 a.m. Pacific Time. The decision to adjourn was made to ensure that shareholders have ample opportunity to express their opinions on critical proposals outlined in Vaxart's proxy statement.
Importance of Participation in Voting
The company is encouraging all shareholders who are on record as of March 26, 2025, to cast their votes by June 12, 2025, at 11:59 p.m. Eastern Time. This initiative aims to empower stockholders to partake actively in the company's strategic direction, particularly concerning significant proposals that might affect its future.
Independent Proxy Advisory Firms Endorse Proposal
Vaxart's leadership has recently engaged with several major shareholders, addressing their queries about the reverse stock split proposal. During these discussions, a majority have expressed their intent to support Proposal No. 2. This is viewed as a crucial step for the company, ensuring it continues its listing on the Nasdaq exchange while preparing for the phenomenal milestones ahead.
About the Upcoming Virtual Meeting
The reconvened annual meeting will take place in a virtual-only format. Shareholders can access the meeting by visiting the designated virtual meeting site and entering the control number that was provided in their proxy materials. This adaptation allows stockholders to engage with the proceedings conveniently.
Voting Procedures and Proxy Information
Vaxart continues to solicit votes from stockholders on all proposals included in the proxy statement. Please note that proxies already submitted for the annual meeting will be counted at the adjourned meeting, reaffirming the importance of participation even after the initial voting period.
Guidance from Proxy Advisory Firms
Institutional Shareholder Services (ISS) and Glass Lewis, both respected independent proxy advisory firms, have recommended that stockholders vote in support of Proposal No. 2. The guidance from these firms reflects a broader consensus on the significance of this proposal for Vaxart's future growth and strategy.
Understanding Vaxart's Innovations
Vaxart is at the forefront of biopharmaceutical advancements, developing oral recombinant vaccines using its proprietary delivery platform. This innovative approach allows vaccines to be distributed in pill form, negating the need for refrigeration and reducing the risks connected to traditional needle vaccinations. Current development programs include vaccines targeting diseases like coronavirus, norovirus, and influenza, along with a therapeutic vaccine aimed at HPV.
Commitment to Innovation and Patenting
The company is actively pursuing patent protection for its unique technology, including those related to adenovirus and TLR3 agonists that facilitate oral vaccination. This commitment to protecting its intellectual property underscores Vaxart's dedication to revolutionizing vaccine delivery and efficacy.
Shareholder Support and Communication
Vaxart remains focused on maintaining open lines of communication with its shareholders. The company provides a wealth of information about its current initiatives and future directions on its investor relations website, ensuring all stakeholders are well-informed and engaged.
Frequently Asked Questions
What is the new date for Vaxart's annual meeting?
The annual meeting has been rescheduled to June 13, 2025, at 8:30 a.m. Pacific Time.
How can shareholders vote?
Shareholders can cast their votes by June 12, 2025, at 11:59 p.m. Eastern Time using the control number provided in their proxy materials.
What is the purpose of Proposal No. 2?
Proposal No. 2 involves a reverse stock split, which has garnered support from key shareholders and advisory firms as a necessary step to maintain Nasdaq listing.
How can shareholders participate in the virtual meeting?
Shareholders can join the virtual meeting by visiting the specified website and entering their control number from the proxy materials.
Who should shareholders contact for assistance?
Shareholders with questions regarding voting can reach out to Vaxart's proxy solicitation firm, Campaign Management, LLC at 1-855-264-1527 or via email at info@campaign-mgmt.com.
